DAPK inhibition mimics ibrutinib‐induced repression of both IEG mRNA and histone H3 phosphorylation and has anti‐proliferative effect comparable to ibrutinib in CLL in vitro. The gene discussed is DAPK1; the disease is B-cell chronic lymphocytic leukemia.